Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD).
| NEW YORK, Oct. 19, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh explants of ulcerative colitis and Crohn’s disease tissues will be used to investigate the therapeutic potential of Hoth’s HT-003 drugs. All testing will be performed at REPROCELL’s Centre for Predictive Drug Discovery in Glasgow.
“We are delighted to extend this human tissue testing project with Hoth,” said Dr David Bunton, CEO of REPROCELL’s Center for Predictive Drug Discovery. “They have been a fantastic team to work with, and we have obtained promising data for the HT-003 therapeutic platform so far,” he continued. “Our team love to know we are contributing to the development of potential new medicines,” stated Cristina Linde, Reprocell’s Study Director for the project. “REPROCELL’s IBD culture studies have dynamically informed the potential of the HT-003 therapeutic platform, including focusing future development on lead candidate molecules with optimized target responses for ulcerative colitis and Crohn’s disease,” said Dr. Stefanie Johns, Chief Scientific Officer of Hoth Therapeutics. “The volume and quality of data we have been able to gather from these studies in a short amount of time is remarkable,” stated Dr. Johns. REPROCELL’s IBD culture studies use fresh intestinal tissues donated by IBD patients to predict human drug behavior. By measuring the levels of inflammatory markers contained in tissue explants before and after drug administration, researchers can determine whether a compound is likely to demonstrate significant efficacy during clinical trials. Human tissue research is known to be highly translational because the original structure, composition, and genetic content of tissues are maintained throughout experimentation. In REPROCELL’s IBD culture studies, over 40 inflammatory mediators can be measured and in a range of tissue types, including healthy, Crohn’s, or ulcerative colitis. Tissue cytokine profiles from these studies reflect clinical responses to drugs, and several end-points can be assessed including multiplex ELISA, gene expression, or immunohistochemistry. You can find out more on the REPROCELL website. About Hoth Therapeutics, Inc: Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth’s pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis, and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/. About REPROCELL: REPROCELL (formerly Biopta) is a contract research organization (CRO) that uses fresh tissues to predict drug behavior in humans. The company’s 24/7 global tissue network and GLP lab operation are unique within the Pharma industry, allowing unrivaled access to human functional tissues and customized fee-for-service contract research. You can find out more about REPROCELL’s human fresh tissue studies at: https://www.reprocell.com/drug-efficacy-safety-adme Forward-Looking Statement This press release includes forward-looking statements based upon Hoth’s current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth’s business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management’s expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled “Risk Factors” in Hoth’s most recent Annual Report on Form 10-K and Hoth’s other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth’s current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. Contact
SOURCE Hoth Therapeutics, Inc. | ||
Company Codes: NASDAQ-NMS:HOTH |
View original content to download multimedia:
